Three insights that will change how you approach integrated delivery networks

Healthcare reform and financial pressures are leading to increased integration within siloed organizations across healthcare systems. Integrated delivery networks (IDNs) are growing in importance for pharmaceutical manufacturers as they now represent the majority of the healthcare spend in the USA, writes Theresa Greco, vice president, life sciences, health care, LexisNexis Risk Solutions, in a weekly expert view piece.

Consider this: In the USA, there are 1,500 IDNs with over 67,000 parent/child relationships; 250 group purchasing organizations (GPOs) with more than 94,000 purchasing relationships and 800 accountable care organizations (ACOs) with more than 4,000 relationships to health care and IDNs.1

Business considerations become as important as clinical ones